triple glp-1/gip/glucagon receptor agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 Effects of triple GLP-1/GIP/Glucagon agonists.

Conclusion Tirzepatides approval as the first drug for OSA expands treatment options for patients with both obesity and sleep apnea

Foods high in fiber, proteins, and healthy fats can increase GLP-1

REDUCE HUNGER & CRAVINGS*: Patented Supresa saffron extract is shown to reduce hunger and snacking in as early as 8 weeks in clinical study participants.*

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

At 4,114 Daltons (semaglutide) and 4,813 Daltons (tirzepatide), GLP-1 agonists are 8 to 10 times larger than the typical threshold for easy milk transfer

High acceptance of new drug therapies, presence of major drug manufacturers and rising awareness among physicians regarding the benefits of incretin-based therapies have been the key growth factors